Special Issue "Advances of Genetic Research on Neuroendocrine Tumors"
Deadline for manuscript submissions: 1 November 2021.
Neuroendocrine tumors (NETs) are rare neoplasms, they represent a heterogeneous group of tumors arising from neuroendocrine cells of the diffuse endocrine system, which occur most frequently in the gastrointestinal tract. Neuroendocrine neoplasms often are associated with fibrosis, which may develop locally or at distant sites, especially NET G2, NET G3 and NEC G3.
Several approaches have been applied on the targeting of CAF-related surface markers, such as FAP and α-SMA since they are highly expressed in a number of tumour tissues, including pancreatic, lung, and breast cancer.
Fibroblast activation protein (FAP)-expressing cancer-associated fibroblasts (CAF), a major component of tumor stroma, confer treatment resistance, promote local progression, metastasis and immunosuppression. Enhancer of zeste homolog 2 (EZH2), a catalytic component of the polycomb repressor complex has intrinsic histone methyl transferase activity, thereby silencing multiple tumor suppressor genes.4 Upregulation of EZH2 promotes cell growth, migration, and invasion. High level of EZH2 expression is associated with poor prognosis, high grade, and high stage. Nowadays, a new study has proved that EZH2 plays an important role in tumor angiogenesis and has been implicated in the progression and metastasis of certain cancers.
Potential topics for this Special Issue include, but are not limited to:
- FAP expression in neuroendocrine tumor;
- Possible role of FAP and EZH2 in the proliferation of neuroendocrine tumors;
- FAP and EZH2 cancer cell tumor environment/stroma communication;
- Inflammatory and immune modulation of tumor microenvironment mediated by FAP and EZH2;
- FAP as therapeutic targets for invasive neuroendocrine tumors.
Dr. Pinuccia Faviana
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Neuroendocrine tumors
- CAF in neuroendocrine tumors
- EZH2 new therapeutic target
- Microenviroment and FAP (fibroblast activation protein) in microenviroment of neuroendocrine tumors